Rationale and design of a randomized trial of early intensive blood pressure lowering on cerebral perfusion parameters in thrombolysed acute ischemic stroke patients

BACKGROUND AND RATIONALE

Uncertainty persists over the optimal management of blood pressure (BP) in the early phase of acute ischemic stroke (AIS). This study aims to determine the safety and effects of intensive BP lowering on cerebral blood flow (CBF) and functional in AIS patients treated with intravenous thrombolysis.

METHODS

In a randomized controlled trial, 54 thrombolysed AIS patients with a systolic BP of 160 to 180 mm Hg will be randomized to early intensive BP lowering (systolic target range 140-160 mm Hg) or guideline-based BP management (systolic range 160-180 mm Hg) during first 72-hours using primarily intravenous labetalol. We hypothesize that early intensive BP lowering will not reduce CBF by 20% and/or increase the volume of hypoperfused tissue by >20% on computed tomographic perfusion. Clinical outcome will be assessed using a dichotomized modified Rankin scale (scores 0-1 as excellent outcome vs scores 2-6 as dead or dependent) at 90 days. Other outcome would be symptomatic intracerebral hemorrhage. The trial is registered at ClinicalTrials.gov, NCT03443596.

CONCLUSION

This randomized study will provide important information about the physiological effects of BP reduction on cerebral perfusion after intravenous thrombolysis in AIS.

Entrance dose measurement: a simple and reliable technique

Verification of tumor dose for patients undergoing external beam radiotherapy is an important part of quality assurance programs in radiation oncology. Among the various methods available, entrance dose in vivo is one reliable method used to verify the tumor dose delivered to a patient. In this work, entrance dose measurements using LiF:Mg;Ti and LiF:Mg;Cu;P thermoluminescent dosimeters (TLDs) without buildup cap was carried out. The TLDs were calibrated at the surface of a water equivalent phantom against the maximum dose, using 6- and 10-MV photon and 9-MeV electron beams. The calibration geometry was such that the TLDs were placed on the surface of the "solid-water" phantom and a calibrated ionization chamber was positioned inside the phantom at calibration depth. The calibrated TLDs were then utilized to measure the entrance dose during the treatment of actual patients. Measurements were also carried out in the same phantom simultaneously to check the stability of the system. The dose measured in the phantom using the TLDs calibrated for entrance dose to 6-and 10-MV photon beams was found to be close to the dose determined by the treatment planning system (TPS) with discrepancies of not more than 4.1% (mean 1.3%). Consequently, the measured entrance dose during dose delivery to the actual patients with a prescribed geometry was found to be compatible with a maximum discrepancy of 5.7% (mean 2.2%) when comparison was made with the dose determined by the TPS. Likewise, the measured entrance dose for electron beams in the phantom and in actual patients using the calibrated TLDs were also found to be close, with maximum discrepancies of 3.2% (mean 2.0%) and 4.8% (mean 2.3%), respectively. Careful implementation of this technique provides vital information with an ability to confidently accept treatment algorithms derived by the TPS or to re-evaluate the parameters when necessary.

A novel approach of dose mapping using a humanoid breast phantom in radiotherapy

A study of dose mapping techniques to investigate the dose distribution throughout a planned target volume (PTV) in a humanoid breast phantom exposed to a 6 MV photon beam similar to that of treatment conditions is described. For tangential breast irradiation using a 6 MV accelerator beam, the dose is mapped at various locations within the PTV using thermoluminescent dosemeters (TLDs) and radiographic films. An average size perspex breast phantom with the ability to hold the dosemeters was made. TLDs were exposed after packing them in various locations in a particular slice, as planned by the treatment planning system (TPS). To map the dose relative to the isocenter, films were exposed after tightly packing them in between phantom slices, parallel to the central axis of the beam. The dose received at every location was compared with the given dose as generated by the TPS. The mapped dose in each location in the isocentric slice from superficial to deep region was found to be in close agreement with the TPS generated dose to within +/-2%. Doses at greater depths and distant medial and lateral ends, however, were found to be lower by as much as 9.4% at some points. The mapped dose towards the superior region and closest inferior region from the isocenter was found to agree with those for TPS. Conversely, results for the farthest inferior region were found to be significantly different with a variance as much as 17.4% at some points, which is believed to be owing to the variation in size and shape of the contour. Results obtained from films confirmed this, showing similar trends in dose mapping. Considering the importance of accurate doses in radiotherapy, evaluating dose distribution using this technique and tool was found to be useful. This provides the opportunity to choose a technique and plan to provide optimum dose delivery for radiotherapy to the breast.